Cencora, Inc. (NYSE:COR) Shares Acquired by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 6,505.4% in the third quarter, Holdings Channel reports. The institutional investor owned 33,027 shares of the company’s stock after buying an additional 32,527 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Cencora were worth $7,767,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. New Millennium Group LLC bought a new position in Cencora during the second quarter worth $26,000. TCTC Holdings LLC bought a new position in Cencora during the first quarter worth $29,000. TFO Wealth Partners LLC bought a new position in Cencora during the first quarter worth $30,000. LRI Investments LLC bought a new position in Cencora during the first quarter worth $31,000. Finally, MFA Wealth Advisors LLC bought a new position in Cencora during the second quarter worth $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on COR shares. Leerink Partners reduced their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Bank of America reissued a “neutral” rating and issued a $245.00 price target (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Robert W. Baird dropped their price target on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research note on Friday, September 6th. Evercore ISI decreased their price objective on Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Finally, Wells Fargo & Company raised their price objective on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $259.44.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,461,153 shares of company stock valued at $1,073,075,720. 15.80% of the stock is currently owned by insiders.

Cencora Stock Performance

Shares of COR traded down $1.98 on Wednesday, reaching $229.79. 65,695 shares of the stock traded hands, compared to its average volume of 1,399,833. The firm has a market cap of $45.83 billion, a price-to-earnings ratio of 25.36, a P/E/G ratio of 1.40 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. Cencora, Inc. has a 12 month low of $182.75 and a 12 month high of $247.66. The stock’s 50-day moving average price is $231.91 and its 200-day moving average price is $230.73.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping the consensus estimate of $3.18 by $0.16. The firm had revenue of $74.20 billion for the quarter, compared to analysts’ expectations of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.92 earnings per share. Equities analysts forecast that Cencora, Inc. will post 13.63 EPS for the current fiscal year.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.